))
Advancing treatment for BPDCN: current therapies, a deep dive into tagraxofusp, & emerging novel agents
Manage episode 456122714 series 2838329
Content provided by VJHemOnc. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJHemOnc or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by involvement of the skin, bone marrow, and lymph nodes, often associated with a poor prognosis. In this podcast episode, Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an in-depth exploration of BPDCN. Dr Pemmaraju discusses the challenges in treating this disease and reviews current therapeutic options such as chemotherapy, tagraxofusp, and transplantation. He takes a deep dive into the CD123-targeted agent tagraxofusp, addressing patient eligibility, the role of tagraxofusp in bridging to transplantation, and real-world data on its use. Additionally, Dr Pemmaraju shares insights into ongoing clinical trials and emerging treatments for BPDCN, including novel CD123-targeted therapies, combination strategies, BCL2 inhibitors, and immunotherapeutic approaches.
200 episodes
Share
